Abstract
Immunotherapy (IO) represents one of the most promising therapeutic approaches in systemic cancer treatment. However, its broad clinical application revealed several important cardiovascular side effects which can limit treatment options, decrease patients' prognosis and quality of life. The aim of this study was to assess the prevalence of cardiovascular risk factors (CVRF) and the incidence of cardiovascular events (CVE) in patients treated with IO. This has been little researched, and the information we have is scarce.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.